COMP <GO>
CVKD vs ERNA // 10Y YIELD & FRED MACRO BETA
Cadrenal Therapeutics Inc. (NASDAQ) VS. Ernexa Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CVKD 1
— ERNA 2
■ METRIC PARITY
LAST: $0.94 (-0.47%) • MKT CAP: $3.4M
macro-sensitivity
—
LAST: $2.11 (+6.57%) • MKT CAP: $3.4M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVKD VS. ERNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CVKD | ERNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ERNA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.6 | 32.3 | +13.31 | CVKD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.4M | $3.4M | -$78.7K | ERNA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CVKD REV | ERNA REV | CVKD GROSS % | ERNA GROSS % | CVKD FCF | ERNA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$12.6M | -$7.1M |
| FY 2024 | $0 | $582.0K | — | 83.5% | -$7.4M | -$16.2M |
| FY 2023 | $0 | $68.0K | — | — | -$3.5M | -$20.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVKD // BETA —
ERNA // BETA —